CHCecilia Hindorf

Cecilia Hindorf

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cecilia Hindorf has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Feasibility of Thorium-227/Radium-223 Gamma-Camera Imaging During Radionuclide Therapy

    by Erik Larsson, Gustav Brolin, Adriaan Cleton, Tomas Ohlsson, Ola Lindén, Cecilia Hindorf

    Thorium-227 ( 227 Th) is a long-lived (T 1/2 = 18.7 d) α-emitter that has emerged as candidate for radioimmunotherapy. Imaging of patients treated with thorium-227 conjugates is challenging due to the low activity administered and to photon emissions with low yields. In addition, the radioactive daughter radium-223 ( 223 Ra) have photon emissions in the same energy range as 227 Th. The long half-life of 223 Ra (T 1/2 = 11.4 d) and the possibility of redistribution motivates efforts to separate 227 Th and 223 Ra. The aim of this study was to investigate the feasibility of imaging of patients treated with 227 Th-labeled-monoclonal antibody (mAb) and to determine acquisition and image processing parameters to enable discrimination between 227 Th and 223 Ra. Imaging was performed with a GE Discovery 670 NM/CT γ-camera. Radionuclide separation with different energy windows (EW) and collimators was studied in images of vials with either 227 Th or 223 Ra. Phantom acquisitions with clinically relevant activities were performed to assess image quality and the usefulness of background subtraction and spatial filtering. Two patients treated with 227 Th-labeled-mAb were imaged. Imaging of vials showed that 223 Ra can be distinguished from 227 Th using multiple energy windows. Medium- and high-energy collimators showed similar performance of sensitivity and spatial resolution, whereas the low-energy collimator had higher sensitivity but poor resolution due to collimator penetration. Visually, the image quality was improved with background subtraction and spatial filtering. The patient images exhibited the expected image quality and a possibility to separate 227 Th and 223 Ra. γ-Camera imaging of patients treated with 227 Th-mAb is feasible and 223 Ra can be distinguished from 227 Th. Image quality is substantially improved using background subtraction and a spatial smoothing filter. Acquisition settings recommended for planar images are: high-energy general purpose or medium-energy general purpose collimator, 40 min acquisition time and energy windows: (1) 70–100 keV ( 227 Th and 223 Ra); (2) 215–260 keV ( 227 Th); (3) 260–290 keV ( 223 Ra); (4) 350–420 keV ( 223 Ra).


  • Open Access

    Comparison of conventional and Si-photomultiplier-based PET systems for image quality and diagnostic performance

    by Jenny Oddstig, Sigrid Leide Svegborn, Helen Almquist, Ulrika Bitzén, Sabine Garpered, Fredrik Hedeer, Cecilia Hindorf, Jonas Jögi, Lena Jönsson, David Minarik, et al.

    Background: A new generation of positron emission tomography with computed tomography (PET-CT) was recently introduced using silicon (Si) photomultiplier (PM)-based technology. Our aim was to compare the image quality and diagnostic performance of a SiPM-based PET-CT (Discovery MI; GE Healthcare, Milwaukee, WI, USA) with a time-of-flight PET-CT scanner with a conventional PM detector (Gemini TF; Philips Healthcare, Cleveland, OH, USA), including reconstruction algorithms per vendor’s recommendations. Methods: Imaging of the National Electrical Manufacturers Association IEC body phantom and 16 patients was carried out using 1.5 min/bed for the Discovery MI PET-CT and 2 min/bed for the Gemini TF PET-CT. Images were analysed for recovery coefficients for the phantom, signal-to-noise ratio in the liver, standardized uptake values (SUV) in lesions, number of lesions and metabolic TNM classifications in patients. Results: In phantom, the correct (> 90%) activity level was measured for spheres ≥17 mm for Discovery MI, whereas the Gemini TF reached a correct measured activity level for the 37-mm sphere. In patient studies, metabolic TNM classification was worse using images obtained from the Discovery MI compared those obtained from the Gemini TF in 4 of 15 patients. A trend toward more malignant, inflammatory and unclear lesions was found using images acquired with the Discovery MI compared with the Gemini TF, but this was not statistically significant. Lesion-to-blood-pool SUV ratios were significantly higher in images from the Discovery MI compared with the Gemini TF for lesions smaller than 1 cm (p < 0.001), but this was not the case for larger lesions (p = 0.053). The signal-to-noise ratio in the liver was similar between platforms (p = 0.52). Also, shorter acquisition times were possible using the Discovery MI, with preserved signal-to-noise ratio in the liver. Conclusions: Image quality was better with Discovery MI compared to conventional Gemini TF. Although no gold standard was available, the results indicate that the new PET-CT generation will provide potentially better diagnostic performance.


  • Open Access

    Quantitative analysis of phantom studies of 111In and 68Ga imaging of neuroendocrine tumours

    by L. Jönsson, A. Stenvall, E. Mattsson, E. Larsson, A. Sundlöv, T. Ohlsson, C. Hindorf

    Background: Nuclear medicine imaging of neuroendocrine tumours is performed either by SPECT/CT imaging, using 111In-octreotide or by PET/CT imaging using 68Ga-radiolabelled somatostatin analogs. These imaging techniques will give different image quality and different detection thresholds for tumours, depending on size and activity uptake. The aim was to evaluate the image quality for 111In-SPECT and 68Ga-PET imaging, i.e. the smallest volume possible to visualize for different source-to-background activity ratios. The accuracy of quantification of lesion volume and activity was also investigated to develop an objective evaluation for radionuclide therapy eligibility. The phantom study was performed using the NEMA IEC Body Phantom with six hot spheres having inner diameters of 10, 13, 17, 22, 28, and 37 mm, filled with either 68Ga or 111In with sphere-to-background ratios (SBRs) of no background activity, 5:1, 2.5:1, and 1.25:1. Activity ratios of 1.25:1 and 2.5:1 are clinically found for lesions close to the liver and spleen. Clinical acquisition and reconstruction protocols were applied. Line profiles were drawn to evaluate the smallest detectable volume within a given SBR. Recovery curves based on threshold-based VOIs, threshold-based VOIs adapted to the background and CT-based ROIs were obtained for all SBRs and sphere diameters, allowing for quantification. Results: The 10-mm sphere was not possible to detect in SPECT images. It was detectable in PET images for SBRs of 2.5:1 and higher. In a background corresponding to the activity uptake in the liver, spheres larger than 22–37 mm were detectable in the 111In-SPECT images and spheres larger than 13–22 mm were detectable in the 68Ga-PET images. The maximum activity concentration was accurately quantified for spheres larger than 22 mm in the PET images; however, the quantification was impaired by sphere size and background activity. Conclusions: It was not possible to detect the 10-mm sphere in any of the SPECT images. In a background corresponding to the activity uptake in the liver, spheres larger than approximately 30 mm were visible in the 111In-SPECT images and spheres larger than approximately 17 mm were visible in the 68Ga-PET images. Sphere diameter and background activity strongly affect the possibility of a correct quantification.


  • Open Access

    Fully quantitative cardiovascular magnetic resonance myocardial perfusion ready for clinical use: a comparison between cardiovascular magnetic resonance imaging and positron emission tomography

    by Henrik Engblom, Hui Xue, Shahnaz Akil, Marcus Carlsson, Cecilia Hindorf, Jenny Oddstig, Fredrik Hedeer, Michael S. Hansen, Anthony H. Aletras, Peter Kellman, et al.


  • Importance of correct patient positioning in myocardial perfusion SPECT when using a CZT camera

    by Cecilia Hindorf, Jenny Oddstig, Fredrik Hedeer, Magnus J. Hansson, Jonas Jögi, Henrik Engblom


    • 1 April 2011
      • Vol. 55  (2) , 198-204

    Clinical dosimetry in the treatment of bone tumors: old and new agents.

    by C Hindorf, Glenn Flux, C Ibisch, F Kraeber Bodéré

    Treatment of multisite, sclerotic bone metastases is successfully performed by radionuclide therapy. Pain palliation is the most common aim for the treatment. Two radiopharmaceuticals are currently approved by the European Medicines Agency ((153)Sm-EDTMP and (89)Sr-Cl₂) whilst other radiopharmaceuticals are at different stages of development, or are approved in some European countries ((186)Re-HEDP, (117)Snm-DTPA and (223)Ra-Cl₂). The tissues at risk for the treatment are bone marrow and normal bone. A review of the methods applied for dosimetry for these tissues and for tumours is performed, including the calculation of S values (the absorbed dose per decay) and optimal procedures on how to obtain biodistribution data for each radiopharmaceutical. The dosimetry data can be used to individualise and further improve the treatment for each patient. Dosimetry for radionuclide therapy of bone metastases is feasible and can be performed in a routine clinical practice.


  • Radium-223 chloride, a first-in-class alpha-pharmaceutical for patients with castration-resistant prostate cancer (CRPC) and bone metastases: Biodistribution/dosimetry compared to overall safety profile.

    by V. Lewington, C. Parker, C. Hindorf, G. Flux, S. Chittenden, G. Sgouros, G. O'Bryan-Tear, A. Aksnes

    E15009 Background: Radium-223 chloride (Alpharadin) is a first-in-class targeted alpha-pharmaceutical with a potent and highly targeted antitumor effect on bone metastases. It has shown a promising survival benefit, a benign safety profile and pain improvement in patients (pts) with bone metastatic CRPC. Biodistribution/dosimetry was evaluated in the context of safety. Methods: 6 pts with bone-metastatic CRPC received 2 radium-223 doses, 100 kBq/kg, 6 weeks apart. Blood, urine and feces were collected before and at regular intervals after injection. Whole body gamma camera imaging determined biodistribution. Radiation dose was calculated with adjustments for GI tract, heart wall, red marrow (RM) and osteogenic cells (OC). It was also taken into consideration that the product emits short range, high energy alpha particles. Overall safety and tolerability were evaluated in 292 pts across all Phase I/II trials. Results: Radium-223 wasrapidly eliminated from blood and taken up in bone (∼60% at 4hr) or excreted into the small intestine. There was <5% urinary and no hepato-biliary excretion. Highest calculated absorbed doses were to OC, RM and lower large intestine wall. In separate studies of 292 pts who had received range administered activities, <1% had CTC grade 4 hematological toxicity, 2-4% had grade 3 toxicity for HB, platelets, neutrophils, WBC. Mainly mild to moderate and reversible AEs were seen in the GI tract. Conclusions: Radium-223 was rapidly sequestered to bone/bone metastases and excreted in the GI tract. Due to the very short range of alpha particles (2-10 cell diameters), only a small volume of RM would have received a significant radiation dose, possibly accounting for the favorable hematologic safety profile.